A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

计划入组 5,485 人 · 首次发布于 2024 年 11 月 4 日

A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine

计划入组 66 人 · 首次发布于 2021 年 10 月 5 日

Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects

计划入组 35 人 · 首次发布于 2020 年 9 月 24 日

VXA-CoV2-3.1

VXA-CoV2-1

VXA-A1.1

BENDYCRAFT COVE LLC

United States

VIA Pharmaceuticals, Inc.

United States

EDWARD VIA VIRGINIA COLLEGE OF OSTEOPATHIC MEDICINE

United States

HHS Halts Vaxart's $460 Million Oral COVID-19 Vaccine Trial Amid Federal mRNA Program Rollback

Allyx Therapeutics Receives $3.3 Million NIH Grant for ALX-001 Clinical Studies in Alzheimer's and Parkinson's

Bain Capital Acquires Mitsubishi Tanabe Pharma in $3.3 Billion Deal